Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions, PerkinElmer Sell GeneTac To Indian Institute of Science

NEW YORK, June 6 – In the first joint sale announced since their $5.5 million legal settlement, Genomic Solutions and PerkinElmer said Wednesday they had sold the GeneTac biochip system to the Indian Institute of Science in Bangalore, India.

The institute will use one component, the G3 Library Management System for colony picking, arraying, gridding, and replicating DNA microarrays. The GeneTac HybStation will be used to hybridize microarrays, and the GeneTac LS IV laser imager will scan arrays for image analysis.

PerkinElmer Life Sciences, which is Genomic Solutions’ exclusive distribution partner for markets outside the US and Japan, led the sale of the system to the Indian Institute.

"We see the sale of our systems in India as an initial indicator of how PerkinElmer and Genomic Solutions will work together seamlessly in the future to meet the needs of genomic and proteomic researchers wherever they are in the world," Genomic Solutions' CEO Jeffrey Williams said in a statement.

This sale follows Genomic Solutions and PerkinElmer’s April 19 settlement of a lawsuit that fundamentally changed the nature of the companies’ long-standing relationship.

In the settlement, Genomic Solutions granted UK distribution rights of its products to PerkinElmer, and agreed to buy back 69 percent of PerkinElmer’s 5.2 percent equity stake in the company for $5.5 million, terminating PerkinElmer’s call right to shares and control of Genomic Solutions stock.

The right, which PerkinElmer acquired under Genomic Solutions’ terms of incorporation, gave PerkinElmer an option to become the sole shareholder in Genomic Solutions. PerkinElmer had initiated the lawsuit back in February, alleging that Genomic Solutions’ proposed transaction with an unnamed third party, which analysts said amounted a merger agreement, would effectively eliminate PerkinElmer’s call right. 

Genomic Solutions said in a conference call shortly after the settlement that its first-quarter revenues had been hurt due to weak sales in Europe and Asia, where PerkinElmer has been its distribution partner.

But Williams assured investors that a stronger distribution agreement it had forged with Perkin Elmer, which includes minimum requirements on sales, would help to ameliorate these problems. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.